featured
2017 Top Stories in Oncology: CAR-T Cell Therapies
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- ASH 2017: CTL019 Produces High 6-Month Response Rates in Highly Pretreated Adult Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Anti-CD19 CAR-T Cell Therapy in Refractory Large B-Cell Lymphoma
- CAR-T on the Road to FDA Approval for Pediatric B-ALL
- FDA Oncology Advisory Committee Recommends Approval of CTL019 for Pediatric, Young Adult Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
- Long-Term Follow-Up of CD19 CAR Therapy in ALL
- FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma [press release]. Silver Spring, MD: US Food and Drug Administration; October 18, 2017.
- FDA approval brings first gene therapy to the United States [press release]. Silver Spring, MD; US Food and Drug Administration; August 30, 2017
-
Buechner J, Grupp SA, Maude SL, et al. Global registration trial of efficacy and safety of CTL019 in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia: update to the interim analysis. Paper presented at 22nd Congress of the European Hematology Association; June 22-25, 2017; Madrid, Spain. Abstract S476.
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma [published online December 10, 2017]. N Engl J Med. DOI: 10.1056/NEJMoa1707447.
Disclosure statements are available on the authors' profiles: